Addex Therapeutics (ADXN.SW stock) trades CHF0.046 pre-market on 04 Mar 2026 as investors prepare for the company’s earnings release on Mar 9, 2026. The biotech’s thin float and recent clinical milestones make the next report a potential trigger. Trading volume of 239,756.00 shares today is above the average 175,947.00, highlighting elevated attention ahead of results.

ADXN.SW stock: Earnings calendar and what to watch

Addex lists its earnings announcement for 09 Mar 2026 and the market is pricing in sensitivity to operational updates. Key items to watch in the release are cash runway commentary, R&D spend, and any trial readouts for Dipraglurant and ADX71149. Management remarks on partnership milestones with Janssen or Indivior could change sentiment quickly.

Financial snapshot and valuation

The stock trades at CHF0.046 with a market cap of CHF6940107.00 and 150,871,899.00 shares outstanding. Recent metrics show EPS -0.06 and PE -0.77, reflecting development-stage losses. Price-to-book is 0.87 and current ratio is 2.01, signalling a modest liquidity cushion but negative earnings. Fifty- and 200-day averages sit near 0.052 and 0.058, respectively, placing current price below both averages.

Clinical and operational catalysts ahead of the report

Addex’s lead programs — Dipraglurant for Parkinson’s levodopa-induced dyskinesia and ADX71149 for epilepsy — remain the primary value drivers. Any trial updates or revised timelines could alter the revenue probability model. Licensing or milestone receipts from existing deals would be a rare positive near-term revenue source and could materially affect cash forecasts.

Technical picture, liquidity and volatility

Technically, ADXN.SW shows oversold signals with RSI 34.91 and key support at the year low CHF0.046 and resistance near CHF0.050 and the year high CHF0.085. On-chain volume today of 239,756.00 vs avg 175,947.00 gives above-normal liquidity for a micro-cap on the SIX. Short-term momentum indicators suggest limited trend strength and elevated risk for volatility around earnings.

Meyka AI grade, forecast and price targets

Meyka AI rates ADXN.SW with a score out of 100: 66.82 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly level at CHF0.05 and a yearly target of CHF0.03164. Based on model scenarios we set a conservative price target CHF0.03 (downside ~34.78%), base CHF0.05 (upside ~8.70%), and bull CHF0.08 (upside ~73.91%). Forecasts are model-based projections and not guarantees.

Earnings-play checklist for traders and investors

Before the report confirm three items: 1) cash runway and capex guidance to estimate dilution risk, 2) specific trial milestones or dates for Dipraglurant or ADX71149, and 3) any licensing cash or milestone recognition. Use position sizing to limit exposure given micro-cap volatility and the stock’s low market cap.

Final Thoughts

ADXN.SW stock sits at CHF0.046 pre-market on 04 Mar 2026 with earnings due 09 Mar 2026, and the upcoming release is likely the dominant near-term catalyst. Our Meyka AI forecast model projects a quarterly figure near CHF0.05, implying roughly +8.70% from the current price, while the one-year model sits at CHF0.03164 (-31.20%). Given the company’s development-stage losses (EPS -0.06) and micro-cap structure, risk remains high but so does event-driven upside if management confirms trial progress or milestone revenue. Investors should weigh a healthy current ratio 2.01 and low debt against ongoing negative margins. As an AI-powered market analysis platform, Meyka AI highlights that the stock’s best-use case for many investors is as a speculative exposure to clinical news rather than a core holding. Forecasts are model-based projections and not guarantees; consider liquidity, potential dilution, and biotech sector dynamics on the SIX in Switzerland before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.